High quality raw material for IVD manufacturing industry

Recombinant antigens for IVD manufacturing industry

Rekom Biotech has a wide portfolio of recombinant antigens for IVD manufacturing industry aimed at the identification of diagnosis of human and animal infectious diseases, as well as allergies.

Our antigens are stored in high versatility buffers, allowing their accessibility to the different IVD platforms in the market. Otherwise, our technical team will do its best to adapt the antigen to your platform. Trust in us, we will find the best solution to your system.

Many of our antigens have been validated by ELISA and Western-blot assays with pre-validated positive and negative specimen sera. In such specific cases, we have developed multi-antigenic molecules in order to increase the sensitivity and specificity of the new antigen, being able to offer last-generation bio-markers which will make your IVD test stands out in the market.

Our last line of products are "ready-to-use" conjugated antigens, which can be used with multiple objectives: plate orientation, nanoparticle and gold binding, as detectors in immunocapture and immunometric formats, etc. In addition, formats such as ELISA-capture or ELISA-DAS can be used directly to reveal the IVD test. For more information, you can visit our blog post about biotinylated antigens.

We guarantee the batch reproducibility of our products. We are certified in ISO 9001, which means that all our procedures are protocolized and we comply with the quality requirements that any company would expect to find in a supplier of bio-reagents.

At Rekom Biotech we have specialized in the design and production of next-generation antigens: chimeras or multi-epitopes antigens which have improved their antigenic properties such as sensitivity and specificity.

We offer a customized technical support. Given our extensive experience in the sector and our great technical capacity, we can offer our clients what they need, even if it is not in the market.

Focused on reducing complexity of logistics and shipping costs, we lyophilize all our products. This significantly reduces the cost of transport, which also does not require dry ice anymore, and facilitates the entry of our product to a greater number of countries, without the need for intermediaries.

Our recombinant antigens are provided for research and commercial use in vitro: not for human in vivo or therapeutic use.

Features Features versatility validation conjugation reproducibility wide-portfolio specifity-and-sensitivity technical-support cost-reduction-and-fast-delivery Versatility (CLIA, Western Blot, Indirect ELISA, Positive control in ELISA for Ab detection,
Double antigen sandwich ELISA, Dot Blot, Capture ELISA, Lateral-Flow) Validation (ELISA, graphics) Conjugation (biotynilated antigens) Reproducibility (gel filtration, SDS-PAGE) Wide portfolio (bacteria, viruses, parasites, fungi, allergies) Specifity and sensitivity Technical support Cost reduction and fast delivery Features


The antigen can be shipped with dry ice or lyophilized. Upon arrival (if liquid), or after reconstitution (if lyophilized), it should be aliquoted in order to avoid repeated freezing and thawing cycles and stored at -20oC to -80oC. Proteins should be maintained frozen at high concentrations.


In order to defrost the protein, maintain the aliquot at 25oC without shaking to avoid aggregation.


Before making test dilutions and after the protein has been defrosted, it is recommended to remove possible protein aggregates by centrifuging the stock solution, avoiding alterations in the immobilisation of the biomolecule to the solid surface.

During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 µl or less, we recommend tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the containers cap. Although antigens are expressed in non-pathogenic E. coli and P. pastoris and bacterial integrity is destroyed during purification, the protein preparation should be handled as potentially infectious.